Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 6/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.42 |
| ▸ | PDE2A | O00408 | 4/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.39 |
| ▸ | ACSL6 | Q9UKU0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5417434 | 0.92 | PDE3B (0.44) | PPARGPPARADPP4PDE3BPDE3A | |
| SCHEMBL6585534 | 0.89 | PDE10A (0.43) | PDE2ACYP1A2PDE10A | |
| SCHEMBL5420162 | 0.88 | PPARG (0.43) | PPARGPPARADPP4PDE3BPDE3A | |
| SCHEMBL6377586 | 0.86 | DPP4 (0.48) | PPARGPPARADPP4PDE3BPDE3A | |
| SCHEMBL6377580 | 0.86 | PDE3B (0.42) | PPARGPPARADPP4PDE3BPDE3A | |
| SCHEMBL2327181 | 0.83 | PPARG (0.52) | PPARGPPARADPP4PDE3BPDE3A | |
| SCHEMBL5417074 | 0.82 | PPARG (0.49) | PPARGPPARADPP4PDE3BPDE3A | |
| SCHEMBL2329776 | 0.81 | SIRT2 (0.51) | PPARGPPARADPP4PDE3BPDE3A | |
| SCHEMBL6584067 | 0.81 | PDE3B (0.48) | PPARGPPARADPP4PDE3BPDE3A | |
| SCHEMBL6582267 | 0.81 | PDE3B (0.48) | PPARGPPARADPP4PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143439-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-30 | — | — | US | disclosed |
| EP-1404656-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003006438-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143439-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | MSR1, ARG2, CYBB | PPARG 152/4885PPARA 279/4885DPP4 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.